STOCK TITAN

[Form 4] KALA BIO, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Kala Bio Chief Business Officer Darius Kharabi reported a sale of 4,511 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (ranging from $3.87 to $4.12). The transaction was executed under a pre-established 10b5-1 trading plan from November 16, 2021.

Key details of the transaction:

  • The sale was specifically made to cover tax withholding obligations related to RSU vesting from a June 22, 2023 grant
  • Following the transaction, Kharabi maintains beneficial ownership of 62,566 shares, including 28,878 unvested RSUs
  • The transaction was executed as a direct ownership sale
  • The Form 4 was filed through an attorney-in-fact on June 26, 2025

This planned sale under Rule 10b5-1 demonstrates standard executive equity management for tax obligations rather than a discretionary trading decision.

Darius Kharabi, Chief Business Officer di Kala Bio, ha segnalato la vendita di 4.511 azioni ordinarie il 24 giugno 2025, a un prezzo medio ponderato di 4,01 $ per azione (con un intervallo da 3,87 $ a 4,12 $). La transazione è stata eseguita nell'ambito di un piano di trading predefinito 10b5-1 risalente al 16 novembre 2021.

Dettagli principali della transazione:

  • La vendita è stata effettuata specificamente per coprire obblighi fiscali derivanti dalla maturazione di RSU concesse il 22 giugno 2023
  • Dopo la transazione, Kharabi mantiene la proprietà effettiva di 62.566 azioni, inclusi 28.878 RSU non ancora maturate
  • La transazione è stata eseguita come vendita diretta di proprietà
  • Il modulo Form 4 è stato presentato tramite un procuratore il 26 giugno 2025

Questa vendita pianificata ai sensi della Regola 10b5-1 rappresenta una normale gestione delle azioni da parte di un dirigente per adempiere agli obblighi fiscali, e non una decisione di trading discrezionale.

Darius Kharabi, Director Comercial de Kala Bio, reportó la venta de 4.511 acciones comunes el 24 de junio de 2025, a un precio promedio ponderado de $4.01 por acción (con un rango de $3.87 a $4.12). La transacción se ejecutó bajo un plan de negociación 10b5-1 preestablecido desde el 16 de noviembre de 2021.

Detalles clave de la transacción:

  • La venta se realizó específicamente para cubrir obligaciones fiscales relacionadas con la adquisición de RSU otorgadas el 22 de junio de 2023
  • Después de la transacción, Kharabi mantiene la propiedad beneficiosa de 62,566 acciones, incluyendo 28,878 RSU no adquiridas
  • La transacción se ejecutó como una venta directa de propiedad
  • El Formulario 4 fue presentado a través de un apoderado el 26 de junio de 2025

Esta venta planificada bajo la Regla 10b5-1 demuestra una gestión estándar de capital ejecutivo para obligaciones fiscales, en lugar de una decisión discrecional de negociación.

칼라 바이오의 최고사업책임자 다리우스 카라비는 2025년 6월 24일에 보통주 4,511주를 주당 가중평균 가격 $4.01 (최저 $3.87에서 최고 $4.12 사이)에 매도했다고 보고했습니다. 이 거래는 2021년 11월 16일에 미리 설정된 10b5-1 거래 계획에 따라 실행되었습니다.

거래 주요 내용:

  • 이번 매도는 2023년 6월 22일에 부여된 RSU 권리 확정에 따른 세금 원천징수 의무를 충당하기 위해 이루어졌습니다
  • 거래 후 카라비는 28,878주의 미확정 RSU를 포함하여 총 62,566주의 실질 소유권을 유지합니다
  • 거래는 직접 소유권 매도로 진행되었습니다
  • Form 4 서류는 2025년 6월 26일 대리인을 통해 제출되었습니다

10b5-1 규정에 따른 이번 계획된 매도는 임원의 세금 의무 관리를 위한 표준적인 주식 관리 행위로, 임의적인 거래 결정이 아님을 보여줍니다.

Darius Kharabi, Directeur Commercial de Kala Bio, a déclaré la vente de 4 511 actions ordinaires le 24 juin 2025, à un prix moyen pondéré de 4,01 $ par action (allant de 3,87 $ à 4,12 $). La transaction a été réalisée dans le cadre d’un plan de négociation 10b5-1 préétabli depuis le 16 novembre 2021.

Détails clés de la transaction :

  • La vente a été effectuée spécifiquement pour couvrir les obligations fiscales liées à l’acquisition des RSU attribuées le 22 juin 2023
  • Après la transaction, Kharabi conserve la propriété effective de 62 566 actions, dont 28 878 RSU non acquises
  • La transaction a été réalisée par une vente directe de propriété
  • Le formulaire 4 a été déposé par un mandataire le 26 juin 2025

Cette vente planifiée dans le cadre de la règle 10b5-1 illustre une gestion standard des actions par un cadre pour répondre aux obligations fiscales, plutôt qu’une décision de trading discrétionnaire.

Darius Kharabi, Chief Business Officer von Kala Bio, meldete am 24. Juni 2025 den Verkauf von 4.511 Stammaktien zu einem gewichteten Durchschnittspreis von 4,01 $ pro Aktie (Spanne von 3,87 $ bis 4,12 $). Die Transaktion wurde im Rahmen eines vorab festgelegten 10b5-1 Handelsplans vom 16. November 2021 durchgeführt.

Wichtige Details zur Transaktion:

  • Der Verkauf erfolgte gezielt, um Steuerabzugsverpflichtungen im Zusammenhang mit der RSU-Vesting aus einer Zuteilung vom 22. Juni 2023 zu erfüllen
  • Nach der Transaktion hält Kharabi weiterhin den wirtschaftlichen Eigentum an 62.566 Aktien, darunter 28.878 unverfallene RSUs
  • Die Transaktion wurde als direkter Eigentumsverkauf ausgeführt
  • Das Formular 4 wurde am 26. Juni 2025 durch einen Bevollmächtigten eingereicht

Dieser geplante Verkauf gemäß Regel 10b5-1 zeigt eine übliche Verwaltung von Führungskräfteaktien zur Erfüllung von Steuerpflichten und nicht eine willkürliche Handelsentscheidung.

Positive
  • None.
Negative
  • None.

Darius Kharabi, Chief Business Officer di Kala Bio, ha segnalato la vendita di 4.511 azioni ordinarie il 24 giugno 2025, a un prezzo medio ponderato di 4,01 $ per azione (con un intervallo da 3,87 $ a 4,12 $). La transazione è stata eseguita nell'ambito di un piano di trading predefinito 10b5-1 risalente al 16 novembre 2021.

Dettagli principali della transazione:

  • La vendita è stata effettuata specificamente per coprire obblighi fiscali derivanti dalla maturazione di RSU concesse il 22 giugno 2023
  • Dopo la transazione, Kharabi mantiene la proprietà effettiva di 62.566 azioni, inclusi 28.878 RSU non ancora maturate
  • La transazione è stata eseguita come vendita diretta di proprietà
  • Il modulo Form 4 è stato presentato tramite un procuratore il 26 giugno 2025

Questa vendita pianificata ai sensi della Regola 10b5-1 rappresenta una normale gestione delle azioni da parte di un dirigente per adempiere agli obblighi fiscali, e non una decisione di trading discrezionale.

Darius Kharabi, Director Comercial de Kala Bio, reportó la venta de 4.511 acciones comunes el 24 de junio de 2025, a un precio promedio ponderado de $4.01 por acción (con un rango de $3.87 a $4.12). La transacción se ejecutó bajo un plan de negociación 10b5-1 preestablecido desde el 16 de noviembre de 2021.

Detalles clave de la transacción:

  • La venta se realizó específicamente para cubrir obligaciones fiscales relacionadas con la adquisición de RSU otorgadas el 22 de junio de 2023
  • Después de la transacción, Kharabi mantiene la propiedad beneficiosa de 62,566 acciones, incluyendo 28,878 RSU no adquiridas
  • La transacción se ejecutó como una venta directa de propiedad
  • El Formulario 4 fue presentado a través de un apoderado el 26 de junio de 2025

Esta venta planificada bajo la Regla 10b5-1 demuestra una gestión estándar de capital ejecutivo para obligaciones fiscales, en lugar de una decisión discrecional de negociación.

칼라 바이오의 최고사업책임자 다리우스 카라비는 2025년 6월 24일에 보통주 4,511주를 주당 가중평균 가격 $4.01 (최저 $3.87에서 최고 $4.12 사이)에 매도했다고 보고했습니다. 이 거래는 2021년 11월 16일에 미리 설정된 10b5-1 거래 계획에 따라 실행되었습니다.

거래 주요 내용:

  • 이번 매도는 2023년 6월 22일에 부여된 RSU 권리 확정에 따른 세금 원천징수 의무를 충당하기 위해 이루어졌습니다
  • 거래 후 카라비는 28,878주의 미확정 RSU를 포함하여 총 62,566주의 실질 소유권을 유지합니다
  • 거래는 직접 소유권 매도로 진행되었습니다
  • Form 4 서류는 2025년 6월 26일 대리인을 통해 제출되었습니다

10b5-1 규정에 따른 이번 계획된 매도는 임원의 세금 의무 관리를 위한 표준적인 주식 관리 행위로, 임의적인 거래 결정이 아님을 보여줍니다.

Darius Kharabi, Directeur Commercial de Kala Bio, a déclaré la vente de 4 511 actions ordinaires le 24 juin 2025, à un prix moyen pondéré de 4,01 $ par action (allant de 3,87 $ à 4,12 $). La transaction a été réalisée dans le cadre d’un plan de négociation 10b5-1 préétabli depuis le 16 novembre 2021.

Détails clés de la transaction :

  • La vente a été effectuée spécifiquement pour couvrir les obligations fiscales liées à l’acquisition des RSU attribuées le 22 juin 2023
  • Après la transaction, Kharabi conserve la propriété effective de 62 566 actions, dont 28 878 RSU non acquises
  • La transaction a été réalisée par une vente directe de propriété
  • Le formulaire 4 a été déposé par un mandataire le 26 juin 2025

Cette vente planifiée dans le cadre de la règle 10b5-1 illustre une gestion standard des actions par un cadre pour répondre aux obligations fiscales, plutôt qu’une décision de trading discrétionnaire.

Darius Kharabi, Chief Business Officer von Kala Bio, meldete am 24. Juni 2025 den Verkauf von 4.511 Stammaktien zu einem gewichteten Durchschnittspreis von 4,01 $ pro Aktie (Spanne von 3,87 $ bis 4,12 $). Die Transaktion wurde im Rahmen eines vorab festgelegten 10b5-1 Handelsplans vom 16. November 2021 durchgeführt.

Wichtige Details zur Transaktion:

  • Der Verkauf erfolgte gezielt, um Steuerabzugsverpflichtungen im Zusammenhang mit der RSU-Vesting aus einer Zuteilung vom 22. Juni 2023 zu erfüllen
  • Nach der Transaktion hält Kharabi weiterhin den wirtschaftlichen Eigentum an 62.566 Aktien, darunter 28.878 unverfallene RSUs
  • Die Transaktion wurde als direkter Eigentumsverkauf ausgeführt
  • Das Formular 4 wurde am 26. Juni 2025 durch einen Bevollmächtigten eingereicht

Dieser geplante Verkauf gemäß Regel 10b5-1 zeigt eine übliche Verwaltung von Führungskräfteaktien zur Erfüllung von Steuerpflichten und nicht eine willkürliche Handelsentscheidung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kharabi Darius

(Last) (First) (Middle)
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE

(Street)
ARLINGTON MA 02476

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF BUSINESS OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/24/2025 S 4,511(1) D $4.01(2) 62,566(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. Includes 28,878 unvested RSUs.
/s/ Mary Reumuth, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many KALA shares did Chief Business Officer Darius Kharabi sell on June 24, 2025?

Darius Kharabi sold 4,511 shares of KALA common stock on June 24, 2025, at a weighted average price of $4.01 per share.

What was the purpose of KALA insider Kharabi's stock sale in June 2025?

The sale was made pursuant to a 10b5-1 trading plan adopted on November 16, 2021, specifically to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) granted on June 22, 2023.

What is the price range at which KALA shares were sold by Kharabi?

The shares were sold in multiple transactions at prices ranging from $3.87 to $4.12 per share, with a weighted average price of $4.01.

How many KALA shares does Darius Kharabi own after the June 2025 transaction?

Following the reported transaction, Kharabi beneficially owns 62,566 shares directly, which includes 28,878 unvested restricted stock units (RSUs).

When was KALA CBO Kharabi's 10b5-1 trading plan established?

Darius Kharabi's 10b5-1 trading plan was adopted on November 16, 2021.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

25.94M
5.78M
4.12%
58.58%
4.66%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON